Literature DB >> 18349123

Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Oliver Bock1, Julia Höftmann, Katharina Theophile, Kais Hussein, Birgitt Wiese, Jerome Schlué, Hans Kreipe.   

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasia characterized by progressive deposition of extracellular matrix components in the bone marrow. The involvement of members of the bone morphogenetic protein (BMP) family in aberrant bone marrow matrix homeostasis in PMF has not yet been investigated. Therefore, we analyzed expression of BMP1, an activator of latent transforming growth factor beta-1 (TGFbeta-1) and processor of collagen precursors, and other BMPs in bone marrow from PMF patients and controls (n = 95). Expression of BMP1, BMP6, BMP7, and BMP-receptor 2 was significantly increased in advanced stages of myelofibrosis compared with controls (P < or = 0.01), and enhanced levels of BMP6 expression were already evident in prefibrotic stages of PMF. Immunohistochemistry showed that bone marrow stromal cells and megakaryocytes were the major cellular sources of BMP1 protein. Because TGFbeta-1 and basic fibroblast growth factor have been shown to be important in the development of myelofibrosis, we studied the induction of BMPs by these cytokines in cultured fibroblasts. Fibroblasts treated with TGFbeta-1 showed a pronounced up-regulation of BMP6, suggesting that stromal cells may be susceptible to BMP activation by cytokines with a proven role in the pathogenesis of PMF. We conclude that BMP family members may play an important role in the pathogenesis of myelofibrosis in PMF and are apparently induced by cytokines such as TGFbeta-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349123      PMCID: PMC2276425          DOI: 10.2353/ajpath.2008.071030

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  One-step extraction of RNA from archival biopsies.

Authors:  O Bock; H Kreipe; U Lehmann
Journal:  Anal Biochem       Date:  2001-08-01       Impact factor: 3.365

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

Authors:  Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

4.  Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression.

Authors:  Oliver Bock; Jerome Schlué; Ulrich Lehmann; Reinhard von Wasielewski; Florian Länger; Hans Kreipe
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

Review 5.  The bone morphogenetic protein 1/Tolloid-like metalloproteinases.

Authors:  Delana R Hopkins; Sunduz Keles; Daniel S Greenspan
Journal:  Matrix Biol       Date:  2007-05-18       Impact factor: 11.583

Review 6.  Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Ann Hematol       Date:  1999-10       Impact factor: 3.673

7.  Authentic matrix vesicles contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta.

Authors:  M D'Angelo; P C Billings; M Pacifici; P S Leboy; T Kirsch
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

8.  Bone morphogenetic protein-1 (BMP-1). Identification of the minimal domain structure for procollagen C-proteinase activity.

Authors:  Nichola Hartigan; Laure Garrigue-Antar; Karl E Kadler
Journal:  J Biol Chem       Date:  2003-03-13       Impact factor: 5.157

9.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Authors:  Hédia Chagraoui; Emiko Komura; Micheline Tulliez; Stéphane Giraudier; William Vainchenker; Françoise Wendling
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

10.  Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.

Authors:  Thomas Buhr; Guntram Büsche; Harald Choritz; Florian Länger; Hans Kreipe
Journal:  Am J Clin Pathol       Date:  2003-01       Impact factor: 2.493

View more
  30 in total

1.  Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Authors:  Elisabetta Antonioli; Alessandra Carobbio; Lisa Pieri; Alessandro Pancrazzi; Paola Guglielmelli; Federica Delaini; Vanessa Ponziani; Niccolò Bartalucci; Lorenzo Tozzi; Alberto Bosi; Alessandro Rambaldi; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

2.  Rare cell proteomic reactor applied to stable isotope labeling by amino acids in cell culture (SILAC)-based quantitative proteomics study of human embryonic stem cell differentiation.

Authors:  Ruijun Tian; Shuai Wang; Fred Elisma; Li Li; Hu Zhou; Lisheng Wang; Daniel Figeys
Journal:  Mol Cell Proteomics       Date:  2010-06-08       Impact factor: 5.911

Review 3.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 4.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

5.  First evidence of bone morphogenetic protein 1 expression and activity in sheep ovarian follicles.

Authors:  Elizabeth Canty-Laird; Gwenn-Aël Carré; Béatrice Mandon-Pépin; Karl E Kadler; Stéphane Fabre
Journal:  Biol Reprod       Date:  2010-03-31       Impact factor: 4.285

6.  Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs.

Authors:  Danny Jonigk; Marlene Merk; Kais Hussein; Lavinia Maegel; Katharina Theophile; Michaela Muth; Ulrich Lehmann; Clemens L Bockmeyer; Michael Mengel; Jens Gottlieb; Tobias Welte; Axel Haverich; Heiko Golpon; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 7.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

Review 8.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Authors:  S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

9.  Cytokine expression in muscle following traumatic injury.

Authors:  Wesley M Jackson; Amber B Aragon; Jun Onodera; Steven M Koehler; Youngmi Ji; Jamie D Bulken-Hoover; Jared A Vogler; Rocky S Tuan; Leon J Nesti
Journal:  J Orthop Res       Date:  2011-03-30       Impact factor: 3.494

Review 10.  [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].

Authors:  A H Schmitt-Graeff
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.